Modulating Wnt Signaling Pathway to Enhance Allograft Integration in Orthopedic Trauma Treatment
Final rept. 30 Sep 2010-29 Mar 2014
RUSH UNIV MEDICAL CENTER CHICAGO IL
Pagination or Media Count:
The research project was designed to test a novel approach of modulating Wnt signaling pathway in the bone tissue repair by using monoclonal antibodies against sclerostin Sost and DKK-1 donated by Amgen Inc., Thousand Oaks, CA under MTA. Since the previous annual report, the project has progressed at a rapid pace. We resolved all initial technical difficulties and successfully completed all the surgical procedures, harvested samples at prescribe time points and evaluated new bone formation at the allograft site using CT scans and partially completed mechanical testing. Data presented in report reveals statistically that use of anti-Sost or anti-Dkk-1 antibodies enhances new bone formation around the allograft over all time points. Anti-Dkk-1 antibody treatment also seems to be superior to anti-Sost treatment. Mechanical testing of all available samples show increasing strength over time with Dkk-1-Ab being most effective. Freeze dried allografts performed better than fresh frozen allografts. Data obtained from this study supports our hypothesis.
- Anatomy and Physiology
- Medicine and Medical Research